Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
Summary
The USPTO published patent application US20260092038A1 disclosing novel cannabinoid receptor 1 (CB1) antagonists/inverse agonists for treating metabolic disorders including diabetes, dyslipidemia, cardiovascular disorders, obesity, and cancer. Invented by Marshall Morningstar, the application covers compound compositions and therapeutic uses. Filing date was September 26, 2025.
What changed
The USPTO published a patent application disclosing compounds suitable as cannabinoid receptor 1 antagonists or inverse agonists. The inventions are directed toward treating diabetic disorders, dyslipidemia, cardiovascular disorders, inflammatory disorders, hepatic disorders, cancer, obesity, and comorbidities thereof. The application includes composition claims and methods of treatment using the disclosed compounds.
Patent application publication does not impose immediate compliance obligations. Pharmaceutical and biotechnology companies researching CB1 receptor modulators should review the application to assess potential freedom-to-operate implications or licensing opportunities. The patent application number is 19341744, with CPC classifications spanning heterocyclic compounds and pharmaceutical compositions.
What to do next
- Review patent application for freedom-to-operate assessment
- Evaluate potential licensing opportunities for CB1 antagonist compounds
- Monitor patent prosecution for scope limitations
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF
Application US20260092038A1 Kind: A1 Apr 02, 2026
Inventors
Marshall MORNINGSTAR
Abstract
Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.
CPC Classifications
C07D 231/06 A61K 31/415 A61K 31/4155 A61K 31/454 A61K 31/496 A61K 31/5377 A61K 31/551 A61K 31/553 A61K 38/26 C07D 401/12 C07D 403/12 C07D 405/12 C07D 413/12
Filing Date
2025-09-26
Application No.
19341744
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.